Health & Environmental Research Online (HERO)


Print Feedback Export to File
7696994 
Journal Article 
SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies 
Huang, L; Rong, Y; Pan, Q; Yi, K; Tang, X; Zhang, Q; Wang, W; Wu, J; Wang, F; , 
2021 
SHENYANG PHARMACEUTICAL UNIV 
SHENYANG 
136-146 
English 
32905011 
WOS:000645289700003 
The development of a massively producible vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, is essential for stopping the current coronavirus disease (COVID-19) pandemic. A vaccine must stimulate effective antibody and T cell responses in vivo to induce long-term protection. Scientific researchers have been developing vaccine candidates for the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) since the outbreaks of these diseases. The prevalence of new biotechnologies such as genetic engineering has shed light on the generation of vaccines against novel viruses. In this review, we present the status of the development of coronavirus vaccines, focusing particularly on the biomimetic nanoparticle technology platform, which is likely to have a major role in future developments of personalized medicine.